About CA125 + HE4

About CA125 + HE4

The new CA125 + HE4 risk stratification tool is a differential diagnostic for women presenting with pelvic mass to help determine the most appropriate course of care.

In a recent study, published in the journal Gynecologic Oncology, researchers found that the combination of CA125 and HE4 could lead to accurate detection of ovarian cancer in women with pelvic mass. 531 patients with a pelvic mass were evaluated using CA125, HE4, and the Risk of Ovarian Malignancy Algorithm (ROMA).

The combination test correctly classified 89% of epithelial ovarian cancers and low malignant potential tumors as high risk and 75% of benign disease as low risk. The negative predictive value for the combined population was 93.9%, meaning that there was a false negative rate of only 6%.

The use of this combination assay will help to ensure that patients are given optimal care by stratifying those at high risk to tertiary care centers that specialize in ovarian cancer.

The CA125 + HE4 risk stratification tool predicts the risk of malignancy in women with a pelvic mass.

  • HE4 levels are elevated in more than 50% of tumors that do not express CA125.
  • Combination assay results in a higher sensitivity and specificity than the currently accepted Risk of Malignancy Index (RMI), with 87.4% sensitivity and 56.8% specificity.
  • CA125 + HE4 or HE4 alone have been shown to have greater sensitivity in patients with early stage disease than CA125 alone.
  • The combination of CA125 + HE4 is an accurate tool to stratify women with a pelvic mass at risk for ovarian cancer.